Evidence map›Paper›PMID 31672704›Full record

ArticleJournal of clinical pathology2020

Expression of the checkpoint receptors LAG-3, TIM-3 and VISTA in peripheral T cell lymphomas.

Carlos A Murga-Zamalloa, Noah A Brown, Ryan A Wilcox

Abstract read
In one paragraph

Article in Journal of clinical pathology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. How lactate affects immune strategies in lymphoma.Frontiers in molecular biosciences · 2024
    Review
  6. Review
  7. Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy.Journal of hematology & oncology · 2023
    Review
  8. Review
  9. Review
  10. Review
  11. T cell help in the autoreactive germinal center.Scandinavian journal of immunology · 2022
    Review
  12. Review
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Carlos A Murga-ZamalloaDepartment of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA carlosmu@med.umich.edu.ORCID http://orcid.org/0000-0002-2238-5066
Noah A BrownDepartment of Pathology, University of Michigan, Ann Arbor, Michigan, USA.
Ryan A WilcoxDepartment of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
University of Michigan · US

Funding

Wiskott-Aldrich syndrome protein (WASp) signaling in the oncogenesis of T celllymphomasK08CA218460 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MURGA-ZAMALLOA, CARLOS A. · 2017 to 2019
$320k
NCI NIH HHS K08 CA218460
6 · The paper itself

Abstract

aimsPeripheral T cell lymphomas represent approximately 10%-15% of non-Hodgkin lymphomas and are characterised by an aggressive clinical courses and poor outcomes. Ligands provided by constituents of the tumour microenvironment engage receptors expressed by malignant T cells, promoting tumour growth and chemotherapy resistance. In addition to stimulatory receptors that promote the growth and survival of malignant T cells, recent studies suggest that homologous inhibitory receptors may have an opposing effect and function as tumour suppressors. For example, recent data suggest that programmed cell death 1 blockade may lead to increased lymphoma growth. Therefore, the identification of alternative checkpoint receptors in T cell lymphoproliferative neoplasms is an important and clinically relevant question.

methodsThe checkpoint receptors T cell immunoglobulin-3 (TIM-3), V-domain Ig-containing suppressor of T cell activation (VISTA) and lymphocyte-activation gene 3 (LAG-3) play fundamental roles in peripheral tolerance, and their ligands are exploited by many solid tumours to evade host immunity. However, their expression in T cell lymphoproliferative neoplasms has not been evaluated. In this study, we evaluated the expression of TIM-3, VISTA and LAG-3 in a cohort of peripheral T cell lymphomas cases by immunohistochemistry and flow cytometric analysis.

resultsOur results demonstrate that TIM-3, VISTA and LAG-3 expression is rarely identified within a large cohort of T cell lymphomas and its tumour microenvironment.

conclusionsOur data suggest that immune-regulatory roles for TIM-3, VISTA and LAG-3 may be predominant in lymphomas subsets different than the ones analysed in the current study. However, a potential role for these checkpoint receptors as tumour suppressors in T cell lymphomas remains to be elucidated.

Indexed as

AdultAntigens, CDB7 AntigensHepatitis A Virus Cellular Receptor 2HumansImmunohistochemistryLymphocyte Activation Gene 3 ProteinLymphoma, T-Cell, PeripheralMaleAntigens, CDB7 AntigensHAVCR2 protein, humanHepatitis A Virus Cellular Receptor 2Lag3 protein, humanLymphocyte Activation Gene 3 ProteinVSIR protein, humancheckpoint blockadet-cell lymphoma

Identifiers

PMID31672704
PMCPMC7236306
OpenAlexW2982392171

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.